Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models

O'Connor, M. J.; Odedra, R.; Palakurthi, S.; Hughes, A.; Lai, Z.; Kirschmeier, P.; Zeng, Q.; Zhou, S.; Dharma, S.; Ivanova, E.; Wang, A.; Pierce, A. J.; Yates, J.; Powell, S.; Dougherty, B.; Barrett, J. C.; English, J.; Jewsbury, P.; Matulonis, U. A.; Liu, J. F.

Published in

Elsevier, European Journal of Cancer, (69), p. S142

DOI: 10.1016/s0959-8049(16)33023-4

Tools

Export citation

Search in Google Scholar

Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models

Journal article published in 2016 by M. J. O'Connor, R. Odedra, S. Palakurthi, A. Hughes, Z. Lai, P. Kirschmeier, Q. Zeng, S. Zhou, S. Dharma, E. Ivanova, A. Wang

, A. J. Pierce, J. Yates, S. Powell, B. Dougherty and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) models